WO2002022102A1 - Compositions cosmetiques - Google Patents

Compositions cosmetiques Download PDF

Info

Publication number
WO2002022102A1
WO2002022102A1 PCT/US2000/025085 US0025085W WO0222102A1 WO 2002022102 A1 WO2002022102 A1 WO 2002022102A1 US 0025085 W US0025085 W US 0025085W WO 0222102 A1 WO0222102 A1 WO 0222102A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
vitamin
enzyme
weight
cosmetic composition
Prior art date
Application number
PCT/US2000/025085
Other languages
English (en)
Inventor
Conor James O'prey
Marina Trani
David John Weisgerber
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to MXPA03002169A priority Critical patent/MXPA03002169A/es
Priority to CN00819889.6A priority patent/CN1454080A/zh
Priority to JP2002526354A priority patent/JP2004508393A/ja
Priority to AU2000274826A priority patent/AU2000274826A1/en
Priority to PCT/US2000/025085 priority patent/WO2002022102A1/fr
Priority to EP00963410A priority patent/EP1317249A1/fr
Publication of WO2002022102A1 publication Critical patent/WO2002022102A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to cosmetic compositions.
  • cosmetic compositions comprising a biologically active enzyme, such as a protease enzyme.
  • this invention relates to cosmetic compositions comprising a biologically active enzyme in conjunction with polyhydric alcohol and another skin care active.
  • the compositions have excellent moisturisation, skin softness and skin smoothness benefits.
  • Skin is made up of several layers of cells which coat and protect the keratin and collagen fibrous proteins that form the skeleton of its structure.
  • the outermost of these layers, referred to as the stratum corneum is known to be composed of 25nm protein bundles surrounded by 8nm thick layers.
  • Anionic surfactants and organic solvents typically penetrate the stratum corneum membrane and, by delipidization (i.e. removal ofthe lipids from the stratum corneum), destroy its integrity. This destruction of the skin surface topography leads to a rough feel and may eventually permit the surfactant or solvent to interact with the keratin, creating irritation.
  • Dry, itchy or flaky skin may also result from the failure to maintain a proper water gradient across the stratum corneum.
  • Most of the water needed to maintain the water gradient which is sometimes considered to be the stratum corneum's plasticizer, comes from inside the body. If the humidity is too low, such as in a cold climate, insufficient water remains in the outer layers of the stratum corneum to properly plasticize the tissue, and the skin begins to scale and becomes itchy.
  • enzymes are currently of particular interest as key biological actives in cosmetic compositions to provide skin and hair benefits.
  • examples of such enzymes include proteases which can support or replace ⁇ -hydroxy acids in skin peeling preparations (JP-A-04027388) or which can provide desquamatory action for treatment of dry, itchy or flaky skin (EP-A-0710478); glutathion sulphydryl oxidase which can be used in hair-wave setting (JP-A-4005220); glycosidases which can enhance the process of skin desquamation (WO93/19731) and transglutaminase which can aid the formation of a protective layer on skin, hair and nails (WO94/18945, JP-A-02204407).
  • Water availability within the composition can be measured as water activity, h general the water activity of the compositions is reduced by formulating the aqueous phase of any composition with very high levels of polyhydric alcohol such as glycerine, disclosed in JP 1283213, JP 3294211.
  • polyhydric alcohol such as glycerine
  • Unfortunately such systems have unacceptable aesthetics for cosmetic products. This has been overcome to date by formulation of the aqueous phase into a water in oil emulsion (US 5,932,234 and US 5,830,449) or into a triple water in oil in water emulsion (EP 0779071).
  • a further solution has been to store the product within two different chambers within a single pack wherein the first chamber contians the stabilised enzyme in high levels of polyhydric alcohol and the second chamber contains an aqueous cosmetic composition such that when the two phases are dispensed and mixed the final aqueous composition has acceptable aesthetics (WO 97/27841).
  • the prior art provides useful advances in stabilising enzymes, particularly protease enzymes, within a range of cosmetic compositions it does not sufficiently teach how to stabilise protease enzymes within cosmetic compositions comprising one or more skin care actives such that the benefits of the final product can be expanded beyond those of just the enzyme activity alone.
  • a cosmetic composition suitable for topical application to the skin or hair comprising:
  • the cosmetic compositions of this invention display improved moisturisation efficacy, in addition to skin softness and skin smoothness benefits.
  • a cosmetic method of treatment of the skin or hair comprising applying to the skin or hair a cosmetic composition according to the present invention.
  • biologically active enzyme means the enzyme, wild-type or variant, either per se, or chemically modified by the conjugation of polymer moieties which, at the given level, displays a significant biological, therapeutic or pharmacological benefit.
  • protease enzyme refers to any enzyme whose substrate is a protein.
  • wild-type refers to an enzyme produced by unmutated hosts.
  • the term "variant” means an enzyme having an amino acid sequence which differs from that of the wild-type enzyme due to the genetic mutation of the host producing that enzyme.
  • enzyme activity refers to the activity of 20 ⁇ l of enzyme solution (50ppm) when reacted with the surface of a suitable proteinaceous substrate disc of diameter 1cm, at room temperature over a 30 minute time period.
  • suitable activity is defined as greater than 20% of reaction complete within 30minutes, preferably greater than 50%, more preferably greater than 15%. By using this measure it is defined that enzyme buffers of less than pH 5.5 are not suitable for use with this enzyme.
  • placebo refers to a composition, including cosmetic compositions, which are essentially free from a biologically active enzyme wherein “free from” means that the biologically active enzyme is absent or present at such a low level that it does not deliver the desired end benefit.
  • An example of such a low level would be that the final composition comprises less than 0.0001%, by weight, of a biologically active enzyme.
  • placebo compositions as defined herein may comprise many actives suitable for use on the skin and or hair including those which are known to those skilled in the art including skin care actives such as vitamin complexes, humectants, skin conditioning agents, sun screens and the like.
  • the placebo composition can preferably be formulated such that it is designed to maintain the benefit of the biologically active enzyme throughout phase two ofthe treatment cycle.
  • skin conditioning agent means a material, excluding those materials which are defined as biologically active, which is capable of providing a cosmetic conditioning benefit to the skin such as moisturization, humectancy (i.e. the ability to retain or hold water or moisture in the skin), emolliency, visual improvement of the skin surface and improvement in skin feel.
  • skin hydration refers to an improvement in skin moisture content which can be determined either by technical measures such as by use of a corneometer etc, or expert visual measures for example Fitzpatrick skin dryness scale or by consumer self assessment.
  • the "water activity a w " of a medium containing water is the ratio of the water vapour pressure ofthe product "P H20 product” to the vapour pressure of pure water “PH 20 pure” at the same temperature. It can also be expressed as the ratio ofthe number of molecules of water “N H2O " to the total number of molecules:
  • N H20 + issoived s ubsta nce s which takes account of the molecules of dissolved substances JN dissolved substances •
  • the term "dermatologically-acceptable,” as used herein, means that the compositions, or components thereof, are suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic response, and the like.
  • safe and effective amount means an amount of a compound, component, or composition sufficient to significantly induce a positive benefit, preferably a positive skin appearance or feel benefit, including independently the benefits disclosed herein, but low enough to avoid serious side effects, i.e. to provide a reasonable benefit to risk ratio, within the scope of sound medical judgement.
  • Active and other ingredients useful herein may be categorised or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action. However, it is to be understood that the active and other ingredients useful herein can in some instances provide more than one cosmetic and/or therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated application or applications listed. The elements of these compositions are described in more detail below.
  • compositions can be used for any suitable purpose, h particular, the present compositions are suitable for topical application to the skin or hair, hi particular, the compositions can be in the form of creams, lotions, gels, and the like.
  • cosmetic compositions herein are in the form of an emulsion of one or more oil phases in an aqueous continuous phase.
  • An essential component ofthe present invention is a biologically active enzyme at a level of from about 0.0001% to about 10%, preferably from about 0.001% to about 5%, more preferably from about 0.005% to about 1%, even more preferably from about 0.005% to about 0.5%, by weight, ofthe biologically active enzyme. Whilst these levels are preferred the exact level and range will depend on the type of enzyme being used and the benefit that it delivers. However in all cases the level should be chosen such that the final formulation is both safe and effective.
  • Suitable biologically active enzymes include, but are not necessarily limited to, lipases, phospholipases, glycosidases, lactoperoxidases, protease and cellulases, and mixtures thereof. Protease enzymes are the highly preferred biologically active enzyme for use herein.
  • Protease enzymes are classified under the Enzyme Classification number E.C. 3.4
  • proteases in accordance with the Recommendations (1992) ofthe International Union of Biochemistry and Molecular Biology (IUBMB).
  • Useful proteases are also described in PCT publications: WO 95/30010 published November 9, 1995 by The Procter & Gamble Company; WO 95/30011 published November 9, 1995 by The Procter & Gamble Company; WO 95/29979 published November 9, 1995 by The Procter & Gamble Company.
  • Preferred protease enzymes for use herein are subtilisin, chymotrypsin and elastase-type protease enzymes.
  • subtilisin-type protease enzymes are naturally produced by Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus amylosaccharicus, Bacillus licheniformis, Bacillus lentus and Bacillus subtilis microorganisms.
  • a particularly preferred substilisin-type enzyme is bacterial serine protease enzyme, and variants thereof, obtained from Bacillus amyloliquefaciens, Bacillus licheniformis and/or
  • Bacillus subtilis including Novo Industries A/S Alcalase®, Esperase® , Savinase® (Copenhagen, Denmark), Gist-brocades' Maxatase®, Maxacal® and Maxapem 15®
  • protease enzymes and variants thereof, obtained from Bacillus amyloliquefaciens.
  • Bacillus amyloliquefaciens One known enzyme is BPN'.
  • the wild-type BPN' from Bacillus amyloliquefaciens is characterized by the amino acid sequence:
  • the Gly at position Glyl 66 is replaced with Asn, Ser, Lys, Arg, His, Gin, Ala or Glu; the Gly at position Glyl 69 is replaced with Ser; the Met at position
  • Met222 is replaced with Gin, Phe, Cys, His, Asn, Glu, Ala or Thr; or
  • Met222 is replaced with Cys
  • protease D Another preferred BPN' variant protease, hereafter referred to as "Protease D", is described in WO 95/10615 published April 20, 1995 by Genencor International as characterized by the wild-type BPN' amino acid with mutation to position Asn76, in combination with mutations in one or more other amino acid positions selected from the group consisting of Asp99, SerlOl, Glnl03, Tyrl04, Serl05, Ilel07, Asnl09, Asnl23, Leul26, Glyl27, Glyl28, Leul35, Glul56, Glyl66, Glul95, Aspl97, Ser204, Gln206, Pro210, Ala216, Tyr217, Asn218, Met222, Ser260, Lys265, and/or Ala274.
  • protease F Another preferred BP variant protease, hereafter referred to as "Protease F", is described in U.S. Patent Number 4,760,025, issued to Estell, et al. on July 26, 1988 as characterized by the wild-type BPN' amino acid with mutation to one or more amino acid positions selected from the group consisting of Asp32, Ser33, His64, Tyrl04, Asnl55, Glul56, Glyl 66, Glyl69, Phel89, Tyr217, and Met222.
  • Preferred proteolytic enzymes are selected from the group consisting of Alcalase®, BPN', Protease A, Protease B, Protease D, and Protease F, and mixtures thereof. Protease F is most preferred.
  • compositions for use herein comprise at least one polyhydric alcohol in a concentration of from about 0.1% to about 20%, preferably from about 0.5% to about 18%, more preferably from about 2% to about 15%, and even more preferably from about 5% to about 12% by weight, ofthe polyhydric alcohol, or mixtures thereof.
  • a polyhydric alcohol is considered any organic compound comprising two, or more, alcohol functions or alkoxylated derivatives thereof.
  • the composition has the form of an oil in water emulsion, that the polyhydric alcohol is present in the continuous phase.
  • Suitable polyhydric alcohols for use herein include polyalkylene glycols and more preferably alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, erythritol, threitol, pentaerythritol, xylitol, glucitol, mannitol, hexylene glycol, butylene glycol (e.g., 1,3-butylene glycol), hexane triol (e.g., 1,2,6- hexaiietriol), trimethylol propane, neopentyl glycol, glycerine, ethoxylated glycerine, propane- 1,3 diol, propoxylated glycerine and mixtures thereof.
  • alkylene polyols and their derivatives including propylene
  • polyhydric alcohols of the present invention are selected from glycerine, butylene glycol, propylene glycol, dipropylene glycol, polyethylene glycol, hexane triol, ethoxylated glycerine and propoxylated glycerine, and mixtures thereof.
  • Most preferred polyhydric alcohols for use in the present invention are glycerine, butylene glycol, propylene glycol, polyethylene glycol and mixtures thereof.
  • compositions herein comprise a skin care active at a level from about 0.1% to about 20%, preferably from about 1% to about 10%, more preferably from about 2% to about 8%, by weight.
  • the skin care active for use herein is selected from a vitamin B 3 component, panthenol, vitamin E, vitamin E acetate, retinol, retinyl propionate, retinyl palmitate, retinoic acid, vitamin C, theobromine, ⁇ -hydroxyacid, farnesol, phytantriol, salicylic acid, and mixtures thereof.
  • the preferred skin care active for use herein from the viewpoint of providing improved skin hydration is a vitamin B 3 component.
  • compositions ofthe present invention preferably comprise from about 0.01% to about 20%), more preferably from about 0.1% to about 15%, even more preferably from about 0.5%) to about 10%, and still more preferably from about 1% to about 8%, most preferably from about 1.5% to about 6%, ofthe vitamin B3 compound.
  • vitamin B3 compound means a compound having the formula:
  • R is - CONH2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
  • exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • Suitable esters of nicotinic acid include nicotinic acid esters of C ⁇ -C22 > preferably Cj-
  • non-vasodilating means that the ester does not commonly yield a visible flushing response after application to the skin in the subject compositions (the majority of the general population would not experience a visible flushing response, although such compounds may cause vasodilation not visible to the naked eye).
  • Non-vasodilating esters of nicotinic acid include tocopherol nicotinate and inositol hexanicotinate; tocopherol nicotmate is preferred.
  • a more complete description of vitamin B3 compounds is given in WO 98/22085.
  • vitamin B3 compounds are well known in the art and are commercially available from a number of sources, e.g., the Sigma Chemical Company (St. Louis, MO); ICN Biomedicals, Inc. (Irvin, CA) and Aldrich Chemical Company (Milwaukee, WI).
  • One or more vitamin B3 compounds may be used herein.
  • Preferred vitamin B3 compounds are niacinamide and tocopherol nicotinate. Niacinamide is more preferred.
  • retinoid includes all natural and/or synthetic analogs of Vitamin A or retinol-like compounds which possess the biological activity of Vitamin A in the skin as well as the geometric isomers and stereoisomers of these compounds.
  • the retinoid is preferably retinol, retinol esters (e.g., C2 - C22 alkyl esters of retinol, including retinyl palmitate, retinyl acetate, retinyl proprionate), retinal, and/or retinoic acid (including all-trans retinoic acid and/or 13-cis-retinoic acid), more preferably retinoids other than retinoic acid.
  • retinol esters e.g., C2 - C22 alkyl esters of retinol, including retinyl palmitate, retinyl acetate, retinyl proprionate
  • retinal and/or retinoic acid (including all-trans retinoic acid and/or 13-cis-retinoic acid)
  • retinoic acid including all-trans retinoic acid and/or 13-cis-retinoic acid
  • Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl proprionate, retinal, retinoic acid and combinations thereof. More preferred are retinol, retinoic propionate, retinoic acid and retinyl palmitate.
  • the retinoid may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • compositions preferably contain from or about 0.005% to or about 2%, more preferably 0.01% to about 2% retinoid.
  • Retinol is most preferably used in an amount of from or about 0.01% to or about 0.15%; retinol esters are most preferably used in an amount of from about 0.01% to about 2% (e.g., about 1%).
  • compositions suitable for use in the present invention comprise a vitamin complex consisting of from about 1% to about 5%, by weight, of vitamin B 3 compound or its derivatives; and from about 0.1 % to about 1%, by weight, of a retinol compound or its derivatives in conjunction with from about 0.1% to about 1%, by weight, panthenol or its derivatives.
  • compositions herein can comprise a wide variety of well known optional ingredients.
  • Carrier
  • compositions of the present invention comprise a safe and effective amount of a dermatologically acceptable carrier, suitable for topical application to the skin or hair within which the essential materials and optional other materials are incorporated to enable the essential materials and optional components to be delivered to the skin or hair at an appropriate concentration.
  • a dermatologically acceptable carrier suitable for topical application to the skin or hair within which the essential materials and optional other materials are incorporated to enable the essential materials and optional components to be delivered to the skin or hair at an appropriate concentration.
  • the carrier can thus act as a diluent, dispersant, solvent, or the like for the essential components which ensures that they can be applied to and distributed evenly over the selected target at an appropriate concentration.
  • the carrier can be solid, semi-solid or liquid. Highly preferred carriers are liquid or semi- solid, such as creams, lotions and gels. Preferably the carrier is in the form of a lotion, cream or a gel, more preferably one which has a sufficient thickness or yield point to prevent the particles from sedimenting.
  • the carrier can itself be inert or it can possess dermatological benefits of its own.
  • the carrier should also be physically and chemically compatible with the essential components described herein, and should not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention.
  • the type of carrier ultilised in the present invention depends on the type of product form desired for the composition.
  • the topical compositions useful in the subject invention may be made into a wide variety of product forms such as are known in the art. These include, but are not limited to, lotions, creams, gels, sticks, ointments, pastes and mousses. These product forms may comprise several types of carriers including, but not limited to, solutions, emulsions, and gels.
  • Preferred carriers contain a dermatologically acceptable, hydrophilic diluent.
  • Suitable hydrophilic diluents include water, organic hydrophilic diluents such as Ci - C 4 monohydric alcohols and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g. of MW 200-600), polypropylene glycol (e.g.
  • the diluent is preferably liquid. Water is an especially preferred diluent.
  • the composition preferably comprises at least about 20% of the hydrophilic diluent.
  • Preferred carriers comprise an emulsion comprising a hydrophilic phase, especially an aqueous phase, and a hydrophobic phase e.g., a lipid, oil or oily material.
  • a hydrophilic phase will be dispersed in the hydrophobic phase, or vice versa, to form respectively hydrophilic or hydrophobic dispersed and continuous phases, depending on the composition ingredients, h emulsion technology
  • the term "dispersed phase” is a term well-known to one skilled in the art which means that the phase exists as small particles or droplets that are suspended in and surrounded by a continuous phase.
  • the dispersed phase is also known as the internal or discontinuous phase.
  • the emulsion may be or comprise (e.g., in a triple or other multi-phase emulsion) an oil-in-water emulsion or a water-in-oil emulsion such as a water-in-silicone emulsion.
  • Oil-in-water emulsions typically comprise from about 1% to about 60% (preferably about 1% to about 30%) of the dispersed hydrophobic phase and from about 1% to about 99% (preferably from about 40% to about 90%) ofthe continuous hydrophilic phase; water-in- oil emulsions typically comprise from about 1% to about 98% (preferably from about 40% to about 90%>) of the dispersed hydrophilic phase and from about 1% to about 50% (preferably about 1% to about 30%) of the continuous hydrophobic phase.
  • Preferred compositions herein are oil-in-water emulsions.
  • compositions ofthe present invention may comprise additional humectants which are preferably present at a level of from about 0.01% to about 20%, more preferably from about 0.1% to about 15% and especially from about 0.5% to about 10%.
  • Preferred humectants include, but are not limited to, compounds selected from urea, D or DL panthenol, calcium pantothenate, royal jelly, panthetine, pantotheine, panthenyl ethyl ether, pangamic acid, pyridoxin, pantoyl lactose Vitamin B complex, hexane - 1, 2, 6, - triol, guanidine or its derivatives.
  • Highly preferred humectants are urea, panthenol and mixtures thereof. The above listed compounds may be incorporated singly or in combination.
  • Suitable additional humectants useful herein are sodium 2-pyrrolidone-5-carboxylate (NaPCA), guanidine; glycolic acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium); lactic acid and lactate salts (e.g. ammonium and quaternary alkyl ammonium); aloe vera in any of its variety of forms (e.g., aloe vera gel); hyaluronic acid and derivatives thereof (e.g., salt derivatives such as sodium hyaluronate); lactamide monoethanolamine; acetamide monoethanolamine; urea; panthenol and derivatives thereof; and mixtures thereof.
  • NaPCA sodium 2-pyrrolidone-5-carboxylate
  • guanidine glycolic acid and glycolate salts
  • lactic acid and lactate salts e.g. ammonium and quaternary alkyl ammonium
  • aloe vera in any of
  • At least part (up to about 5% by weight of composition) of an additional humectant can be incorporated in the form of an admixture with a particulate cross-linked hydrophobic acrylate or methacrylate copolymer, itself preferably present in an amount of from about 0.1% to about 10%), which can be added either to the aqueous or disperse phase.
  • This copolymer is particularly valuable for reducing shine and controlling oil while helping to provide effective moisturization benefits and is described in further detail by WO96/03964, incorporated herein by reference.
  • Preferred additional humectants are selected from urea, panthenol and mixtures thereof.
  • Emollients The oil in water emulsions of the present invention generally comprise from about 1% to about 20%, preferably from about 1.5% to about 15%, more preferably from about 0.1 % to about 8%, especially from about 0.5% to about 5%> of a dermatologically acceptable emollient.
  • Emollients tend to lubricate the skin, increase the smoothness and suppleness ofthe skin, prevent or relieve dryness of the skin, and/or protect the skin.
  • Emollients are typically water-immiscible, oily or waxy materials and emollients with high molecular weights can confer tacky properties to a topical composition.
  • suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), contains numerous examples of materials suitable as an emollient.
  • emollients discussed in application WO 00/24372 should be considered as suitable for use in the present invention although preferred examples are outlined in further detail below: i) Straight and branched chain hydrocarbons having from about 7 to about 40 carbon atoms, such as dodecane, squalane, cholesterol, hydrogenated polyisobutylene, isohexadecane, isoeicosane, isooctahexacontane, isohexapentacontahectane, and the C7-C40 isoparaffins, which are C7-C40 branched hydrocarbons.
  • straight and branched chain hydrocarbons having from about 7 to about 40 carbon atoms, such as dodecane, squalane, cholesterol, hydrogenated polyisobutylene, isohexadecane, isoeicosane, isooctahexacontane, isohexapentacontahectane,
  • Suitable branched chain hydrocarbons for use herein are selected from isopentacontaoctactane, petrolatum, and mixtures thereof. Suitable for use herein are branched chain aliphatic hydrocarbons sold under the trade name Permethyl (RTM) and commercially available from Presperse Inc., P.O. Box 735, South Plainfield, N.J. 07080, U.S.A. ii) C1 -C30 alcohol esters of C1 -C30 carboxylic acids, C12-15 alkyl benzoates, and of C2-C30 dicarboxylic acids, e.g. isononyl isononanoate, isostearyl neopentanoate.
  • RTM Permethyl
  • esters are derived from a sugar or polyol moiety and one or more carboxylic acid moieties. Depending on the constituent acid and sugar, these esters can be in either liquid or solid form at room temperature.
  • Examples include: glucose tetraoleate, the galactose tetraesters of oleic acid, the sorbitol tetraoleate, sucrose tetraoleate, sucrose pentaoleate, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate, sorbitol hexaester in which the carboxylic acid ester moieties are palmitoleate and arachidate in a 1:2 molar ratio, and the octaester of sucrose wherein the esterifying carboxylic acid moieties are laurate, linoleate and behenate in a 1:3:4 molar ratio.
  • Other materials include cottonseed oil or soybean oil fatty acid esters of sucrose. Other examples of such materials are described in WO 96/16636, incorporated by reference herein. A particularly preferred material is known by the INCI name sucrose polycottonseedate iv) Vegetable oils and hydrogenated vegetable oils. Examples of vegetable oils and hydrogenated vegetable oils include safflower oil, coconut oil, cottonseed oil, menhaden oil, palm kernel oil, palm oil, peanut oil, soybean oil, rapeseed oil, linseed oil, rice bran oil, pine oil, sesame oil, sunflower seed oil, partially and fully hydrogenated oils from the foregoing sources, and mixtures thereof v) Soluble or colloidally-soluble moisturising agents.
  • hylaronic acid and starch-grafted sodium polyacrylates such as Sanwet (RTM) IM-1000, JJVI-1500 and IM-2500 available from Celanese Superabsorbent Materials, Portsmith, VA, USA and described in USA-A-4,076,663.
  • Preferred emollients for use herein are isohexadecane, isooctacontane, petrolatum, isononyl isononanoate, isodecyl octanoate, isodecyl isononanoate, tridecyl isononanoate, myristyl octanoate, octyl isononanoate, myristyl myristate, methyl isostearate, isopropyl isostearate, C12-15 alkyl benzoates and mixtures thereof.
  • Particularly preferred emollients for use herein are isohexadecane, isononyl isononanoate, methyl isostearate, isopropyl isostearate, petrolatum, or mixtures thereof. Due to its poor skin feel properties castor oil is not a preferred emollient for use herein.
  • compositions herein preferably contain an emulsifier and/or surfactant, generally to help disperse and suspend the disperse phase within the continuous aqueous phase.
  • a surfactant may also be useful if the product is intended for skin cleansing.
  • emulsifiers will be referred to under the term 'surfactants', thus 'surfactant(s)' will be used to refer to surface active agents whether used as emulsifiers or for other surfactant purposes such as skin cleansing.
  • Known or conventional surfactants can be used in the composition, provided that the selected agent is chemically and physically compatible with essential components of the composition, and provides the desired characteristics. Suitable surfactants include non-silicone derived materials, and mixtures thereof.
  • compositions ofthe present invention preferably comprise from about 0.05%> to about 15% of a surfactant or mixture of surfactants.
  • the exact surfactant or surfactant mixture chosen will depend upon the pH ofthe composition and the other components present.
  • Preferred surfactants are nonionic.
  • the nonionic surfactants that are useful herein are those that can be broadly defined as condensation products of long chain alcohols, e.g. Cg-30 alcohols, with sugar or starch polymers ie glycosides.
  • Other useful nonionic surfactants include the condensation products of alkylene oxides with fatty acids (i.e. alkylene oxide esters of fatty acids). These materials have the general formula RCO(X) n OH wherein R is a C ⁇ rj-30 alkyl group, X is -OCH2CH2- (i.e. derived from ethylene glycol or oxide) or -OCH2CHCH3- (i.e.
  • Nonionic surfactants are the condensation products of alkylene oxides with 2 moles of fatty acids (i.e. alkylene oxide diesters of fatty acids). These materials have the general formula RCO(X) n OOCR wherein R is a CJQ-30 a ⁇ yl group, X is -OCH2C ⁇ .2-(i.e. derived from ethylene glycol or oxide) or -OCH2CHCH3-(i.e. derived from propylene glycol or oxide), and n is an integer from about 6 to about 100.
  • An emulsifier for use herein is most preferably a fatty acid ester blend based on a mixture of sorbitan fatty acid ester and sucrose fatty acid ester, especially a blend of sorbiton stearate and sucrose cocoate.
  • This is commercially available from ICI under the trade name Arlatone 2121.
  • Even further suitable examples include a mixture of cetearyl alcohols, cetearyl glucosides such as those available under the trade name Montanov 68 from Seppic and Emulgade PL68/50 available from Henkel..
  • hydrophilic surfactants useful herein can alternatively or additionally include any of a wide variety of cationic, anionic, zwitterionic, and amphoteric surfactants such as are known in the art. See, e.g., McCutcheon's, Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation; U.S. Patent No. 5,011,681 to Ciotti et al., issued April 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al., issued December 20, 1983; and U.S. Patent No. 3,755,560 to Dickert et al., issued August 28, 1973.
  • anionic surfactants are also useful herein. See, e.g., U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975.
  • anionic surfactants are also useful herein. See, e.g., U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975.
  • exemplary anionic surfactants include the alkoyl isethionates (e.g., C12 - C30), alkyl and alkyl ether sulfates and salts thereof, alkyl and alkyl ether phosphates and salts thereof, alkyl methyl taurates (e.g., C 12 - C30), and soaps (e.g., alkali metal salts, e.g., sodium or potassium salts) of fatty acids.
  • alkoyl isethionates e.g., C12 - C30
  • alkyl and alkyl ether sulfates and salts thereof alkyl and alkyl ether phosphates and salts thereof
  • alkyl methyl taurates e.g., C 12
  • amphoteric and zwitterionic surfactants are also useful herein.
  • amphoteric and zwitterionic surfactants which can be used in the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably Cg - Cj g) and one contains an anionic water solubilising group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • alkyl imino acetates examples are alkyl imino acetates, and iminodialkanoates and aminoalkanoates, imidazolinium and ammonium derivatives.
  • Other suitable amphoteric and zwitterionic surfactants are those selected from the group consisting of betaines, sultaines, hydroxysultames, and branched and unbranched alkanoyl sarcosinates, and mixtures thereof.
  • Preferred emulsions of the present invention include a silicone containing emulsifier or surfactant.
  • silicone emulsifiers are useful herein. These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants.
  • Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethyl siloxanes which have been modified to include polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide.
  • dimethicone copolyols examples include alkyl-modified dimethicone copolyols, i.e., compounds which contain C2-C30 pendant side chains.
  • Still other useful dimethicone copolyols include materials having various cationic, anionic, amphoteric, and zwitterionic pendant moieties.
  • compositions ofthe present invention can comprise at least one polymeric thickening agent.
  • the polymeric thickening agents useful herein preferably have a number average molecular weight of greater than 20,000, more preferably greater than 50,000 and especially greater than 100,000.
  • compositions of the present invention may comprise from about 0.01% to about 10%, preferably from about 0.1% to about 8% and most preferably from about 0.5% to about 5% by weight of the composition of the polymeric thickening agent, or mixtures thereof.
  • Preferred polymer thickemng agents for use herein include non-ionic thickening agents and anionic thickening agents, or mixtures thereof.
  • Suitable non-ionic thickening agents include polyacrylamide polymers, crosslinked poly(N-vinylpyrrolidones), polysaccharides, natural or synthetic gums, polyvinylpyrrolidone, and polyvinylalcohol.
  • Suitable anionic thickening agents include acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers and crosslinked copolymers of alkyl vinyl ethers and maleic anhydride.
  • Particularly preferred thickening agents for use herein are the non-ionic polyacrylamide polymers such as polyacrylamide and isoparaffin and laureth-7, available under the trade name Sepigel 305 from Seppic Corporation, and acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold by the B.F. Goodrich Company under the trade mark of Carbopol resins, or mixtures thereof.
  • Suitable Carbopol resins may be hydrophobically modified, and other suitable resins are described in WO98/22085, or mixtures thereof.
  • Silicone Oil The present compositions preferably comprise, at least one silicone oil phase.
  • Silicone oil phase(s) generally comprises from about 0.1% to about 20%, preferably from about 0.5% to about 10%, more preferably from about 0.5% to about 5%, ofthe composition.
  • The, or each, silicone oil phase preferably comprises one or more silicone components.
  • Silicone components can be fluids, including straight chain, branched and cyclic silicones.
  • Suitable silicone fluids useful herein include silicones inclusive of polyalkyl siloxane fluids, polyaryl siloxane fluids, cyclic and linear polyalkylsiloxanes, polyalkoxylated silicones, amino and quaternary ammonium modified silicones, polyalkylaryl siloxanes or a polyether siloxane copolymer and mixtures thereof.
  • the silicone fluids can be volatile or non- volatile.
  • Silicone fluids generally have a weight average molecular weight of less than about 200,000. Suitable silicone fluids have a molecular weight of about 100,000 or less, preferably about 50,000 or less, most preferably about 10,000 or less.
  • the silicone fluid is selected from silicone fluids having a weight average molecular weight in the range from about 100 to about 50,000 and preferably from about 200 to about 40,000.
  • silicone fluids have a viscosity ranging from about 0.65 to about 600,000 mm2.s" i , preferably from about 0.65 to about 10,000 mm ⁇ .s"! at 25°C.
  • the viscosity can be measured by means of a glass capillary viscometer as set forth in Dow Corning Corporate Test Method CTM0004, July 29, 1970.
  • Suitable polydimethyl siloxanes that can be used herein include those available, for example, from the General Electric Company as the SF and Viscasil (RTM) series and from Dow Corning as the Dow Corning 200 series.
  • essentially non-volatile polyalkylarylsiloxanes for example, polymethylphenylsiloxanes, having viscosities of about 0.65 to 30,000 mm ⁇ .s"! at 25°C.
  • These siloxanes are available, for example, from the General Electric Company as SF 1075 methyl phenyl fluid or from Dow Corning as 556 Cosmetic Grade Fluid.
  • Cyclic polydimethylsiloxanes suitable for use herein are those having a ring structure incorporating from about 3 to about 7 (CH3)2SiO moieties.
  • the silicone fluid is selected from dimethicone, decamethylcyclopentasiloxane, octamethylcyclotetrasiloxane, phenyl methicone, and mixtures thereof.
  • Silicone gums can also be used herein.
  • the term "silicone gum” herein means high molecular weight silicones having a weight average molecular weight in excess of about 200,000 and preferably from about 200,000 to about 4,000,000. Iincluded are nonvolatile polyalkyl and polyaryl siloxane gums.
  • a silicone oil phase comprises a silicone gum or a mixture of silicones including the silicone gum.
  • silicone gums typically have a viscosity at 25°C in excess of about 1,000,000 mm ⁇ s'l.
  • the silicone gums include dimethicones as described by Petrarch and others including US-A-4,152,416, May 1, 1979 to Spitzer, et al, and Noll, Walter, Chemistry and Technology of Silicones, New York: Academic Press 1968. Also describing silicone gums are General Electric Silicone Rubber Product Data Sheets SE 30, SE 33, SE 54 and SE 76.
  • silicone gums include polydimethylsiloxane, (polydimethylsiloxane)(methylvinylsiloxane) copolymer, poly(dimethylsiloxane)- (diphenyl)(methylvinylsiloxane) copolymer and mixtures thereof.
  • Preferred silicone gums for use herein are silicone gums having a molecular weight of from about 200,000 to about 4,000,000 selected from dimethiconol, and dimethicone and mixtures thereof.
  • a silicone phase herein preferably comprises a silicone gum incorporated into the composition as part of a silicone gum-fluid blend.
  • the silicone gum When the silicone gum is incorporated as part of a silicone gum-fluid blend, the silicone gum preferably constitutes from about 5% to about 40%), especially from about 10% to 20% by weight of the silicone gum-fluid blend.
  • Suitable silicone gum-fluid blends herein are mixtures consisting essentially of:
  • the ratio of i) to ii) is from about 10:90 to about 20:80 and wherein said silicone gum-based component has a final viscosity of from about 100 mm ⁇ .s " ! to about 100,000 mm ⁇ .s” 1 , preferably from 500 mm ⁇ s -1 to about 10,000 mm ⁇ .s " 1 .
  • An especially preferred silicone-gum fluid blend based component for use in the compositions herein is a dimethiconol gum having a molecular weight of from about 200,000 to about 4,000,000 along with a silicone fluid carrier with a viscosity of about
  • silicone component 0.65 to 100 rnrn ⁇ .s" 1 .
  • An example of this silicone component is Dow Corning Q2-1403 (85% 5 2 ⁇ " 1 Dimethicone Fluid/15% Dimethiconol) and Dow Corning Q2-1401 available from Dow Corning.
  • crosslinked polyorganosiloxane polymers are crosslinked polyorganosiloxane polymers, optionally dispersed in a fluid carrier.
  • the crosslinked polyorganosiloxane polymers together with its carrier (if present) comprises 0.1 % to about 20%, preferably from about 0.5%> to about 10%, more preferably from about 0.5%> to about 5%> of the composition.
  • Such polymers comprise polyorganosiloxane polymers crosslinked by a crosslinking agent. Suitable crosslinking agents are disclosed in WO98/22085. Examples of suitable polyorganosiloxane polymers for use herein include methyl vinyl dimethicone, methyl vinyl diphenyl dimethicone and methyl vinyl phenyl methyl diphenyl dimethicone.
  • crosslinked polyorganosiloxane polymers for use herein are silicone vinyl crosspolymer mixtures available under the tradename KSG supplied by Shinetsu Chemical Co., Ltd, for example KSG-15, KSG-16, KSG-17, KSG-18. These materials contain a combination of crosslinked polyorganosiloxane polymer and silicone fluid. Particularly preferred for use herein especially in combination with the organic amphiphilic emulsifier material is KSG-18.
  • KSG-15, KSG- 16, KSG-17 and KSG-18 are cyclomethicone dimethicone/vinyl dimethicone crosspolymer, dimethicone dimethicone/vinyl dimethicone crosspolymer, cyclomethicone dimethicone/vinyl dimethicone crosspolymer and phenyl trimethicone dimethicone/phenyl vinyl dimethicone crosspolymer, respectively.
  • silicone components suitable for use in a silicone oil phase herein includes polydiorganosiloxane-polyoxyalkylene copolymers containing at least one polydiorganosiloxane segment and at least one polyoxyalkylene segment.
  • Suitable polydiorganosiloxane segments and copolymers thereof are disclosed in WO98/22085.
  • Suitable polydiorganosiloxane-polyalkylene copolymers are available commercially under the tradenames Belsil (RTM) from Wacker-Chemie GmbH, Geschafts Symposium S, Postfach D-8000 Kunststoff 22 and Abil (RTM) from Th.
  • a particularly preferred copolymer fluid blend for use herein includes Dow Corning DC3225C which has the CTFA designation Dimethicone/Dimethicone copolyol.
  • compositions of the present invention preferably comprise an organic sunscreen. Suitable sunscreens can have UVA absorbing properties, UVB absorbing properties or a mixture thereof. The exact amount of the sunscreen active will vary depending upon the desired Sun Protection Factor, ie the "SPF" ofthe composition as well as the desired level of UV protection.
  • the compositions ofthe present invention preferably comprise an SPF of at least 10, preferably at least 15. SPF is a commonly used measure of photoprotection of a sunscreen against erythema. The SPF is defined as a ratio of the ultraviolet energy required to produce minimal erythema on protected skin to that required to products the same minimal erythema on unprotected skin in the same individual. See Federal Register, 43, No 166, pp.
  • compositions of the present invention preferably comprise a UVA absorbing sunscreen actives which absorb UV radiation having a wavelength of from about 320nm to about 400nm.
  • Suitable UVA absorbing sunscreen actives are selected from dibenzoylmethane derivatives, anthranilate derivatives such as methylanthranilate and homomethyl, 1-N-acetylanthranilate, and mixtures thereof.
  • dibenzoylmethane sunscreen actives are described in US Patent No 4,387,089 issued to Depolo; and in Sunscreens: Development, Evaluation, and Regulatory Aspects edited by N. J. Lowe and N. A. Shaath, Marcel Dekker, Inc (1990).
  • the UVA absorbing sunscreen active is preferably present in an amount to provide broad spectrum UVA protection either independently, or in combination with, other UV protective actives which may be present in the composition.
  • Preferred UVA sunscreen actives are dibenzoylmethane sunscreen actives and their derivatives. They include, but are not limited to, those selected from 2- methyldibenzoylmethane, 4-methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4- tert-butyldibenzoylmethane, 2, 4-dimethyldibenzoylmethane, 2, 5- dimethyldibenzoylmethane, 4, 4'-diisopropylbenzoylmethane, 4-(l, l-dimethylethyl)-4'- methoxydibenzoylmethane, 2-methyl-5-isopropyl-4'-methoxydibenzoylmethane, 2- methyl-5-tert-butyl-4'-methoxy-dibenzoylmethane, 2, 4-dimethyl-4'- methoxydibenzoylmethane, 2, 6-dimethyl-4
  • Preferred dibenzoyl sunscreen actives include those selected from 4-(l, l-dimethylethyl)-4'-methoxydibenzoylmethane, 4-isopropyldibenzoylmethane, and mixtures thereof.
  • a more preferred sunscreen active is 4-(l, l-dimethylethyl)-4'- methoxydibenzoylmethane.
  • the sunscreen active 4-(l, l-dimethylethyl)-4'-methoxydibenzoylmethane which is also known as butyl methoxydibenzoylmethane or Avobenzone, is commercially available under the names of Parsol® 1789 from Givaudan Roure (International) S. A. (Basel, Switzerland) and Eusolex® 9020 from Merck & Co., Inc (Whitehouse Station, NJ).
  • the sunscreen 4-isoproplydibenzoyhnethane which is also known as isopropyldibenzoylmethane, is commercially available from Merck under the name of Eusolex® 8020.
  • compositions of the present invention preferably further comprise a UVB sunscreen active which absorbs UV radiation having a wavelength of from about 290nm to abut 320nm.
  • the compositions comprise an amount of the UVB sunscreen active which is safe and effective to provide UVB protection either independently, or in combination with, other UV protective actives which may be present in the compositions.
  • the compositions preferably comprise from about 0.1% to abut 16%, more preferably from about 0.1% to about 12%, and most preferably from about 0.5% to about 8% by weight, of UVB absorbing organic sunscreen.
  • UVB sunscreen actives are suitable for use herein.
  • organic sunscreen actives are described in US Patent No 5,087,372 issued February 11, 1992 to Haffey et al.; and US Patent Nos 5,073,371 and 5,073,372 both issued on December 17, 1991 to Turner et al. and Segarin, et al., at Chapter VJJI, pages 189 et seq., of Cosmetics Science and Technology.
  • Still other useful sunscreens are those disclosed in U.S. Patent No. 4,937,370, to Sabatelli, issued June 26, 1990; and U.S. Patent No. 4,999,186, to Sabatelli et al., issued March 12, 1991.
  • Preferred UVB sunscreen actives are selected from 2-ethylhexyl-2-cyano-3, 2-ethylhexyl N,N-dimethyl-p- aminobenzoate, p-aminobenzoic acid, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-t-butyldibenzoylmethane, 4-isopropyl dibenzoylmethane, 3- benzylidene camphor, 3-(4-methylbenzylidene) camphor, 3 -diphenylacrylate (referred to as octocrylene), 2-phenyl-benzimidazole-5-sulphonic acid (PBSA), cinnamates and their derivatives such as 2-ethylhexyl-p-methoxycinnamate and octyl-p-methoxycinnamate, TEA salicylate, octyldimethyl PABA
  • Preferred organic sunscreen actives are 2-ethylhexyl-2-cyano-3, 3- diphenylacrylate (referred to as octocrylene), 2-phenyl- benzimidazole-5-sulphonic acid (PBSA), octyl-p-methoxycinnamate, and mixtures thereof. Salt and acid neutralised forms ofthe acidic sunscreens are also useful herein.
  • An agent may also be added to any of the compositions useful in the present invention to stabilise the UVA sunscreen to prevent it from photo-degrading on exposure to UV radiation and thereby maintaining its UVA protection efficacy.
  • a wide range of compounds have been cited as providing these stabilising properties and should be chosen to compliment both the UVA sunscreen and the composition as a whole.
  • Suitable stabilising agents include, but are not limited to, those described in US Patents Nos 5,972,316; 5,968,485; 5,935,556; 5,827,508 and Patent WO 00/06110.
  • Preferred examples of stabilising agents for use in the present invention include 2-ethylhexyl-2- cyano-3, 3-diphenylacrylate (referred to as octocrylene), ethyl-2-cyano-3, 3- diphenylacrylate, 2-ethylhexyl-3, 3-diphenylacrylate, ethyl-3, 3-bis(4- methoxyphenyl)acrylate, and mixtures thereof. 2-ethylhexyl-2-cyano-3, 3- diphenylacrylate is most preferred.
  • compositions useful in the present invention may also be added to any of the compositions useful in the present invention to improve the skin substantivity of those compositions, particularly to enhance their resistance to being washed off by water, or rubbed off.
  • a preferred agent which will provide this benefit is a copolymer of ethylene and acrylic acid. Compositions comprising this copolymer are disclosed in U.S. Patent 4,663,157, Brock, issued May 5, 1987. h addition to the organic sunscreens compositions of the present invention can additionally comprise inorganic physical sunblocks. Nonlimiting examples of suitable physical sunblocks are described in CTFA International Cosmetic Ingredient Dictionary, 6 th Edition, 1995, pp. 1026-28 and 1103, Sayre, R. M. et al, "Physical Sunscreens", J. Soc. Cosmet.
  • Preferred inorganic physical sunblocks are zinc oxide and titanium dioxide, and mixtures thereof. When used, the physical sunblocks are present in an amount such that the present compositions are transparent on the skin (ie non-whitening), preferably less than or equal to about 5%. When titanium dioxide is used, it can have an anatase, rutile, or amorphous structure.
  • Physical sunblock particles eg titanium dioxide and zinc oxide
  • a preferred titanium dioxide is commercially available from Tayca (Japan) and is distributed by Tri-K Industries (Emerson, NJ) under the MT micro-ionised series (eg MT 100SAS).
  • compositions of the present invention preferably comprise from about 0.1% to about 10%), more preferably from about 0.1 % to about 4%, and most preferably from about 0.5% to about 2.5%, by weight, of inorganic sunscreen.
  • any additional ingredients can also be added to the compositions herein. It is preferred that any additional ingredients enhance the skin softness / smoothness benefits of the product. In addition it is preferred that any such ingredients do not negatively impact the aesthetic properties ofthe product. As such high levels of proteins such as collagen and elastin are not preferred in compositions useful in the present invention.
  • compositions of the invention can also contain from about 0.01% to about 10%, preferably from about 0.1 % to about 5% of a panthenol moisturizer.
  • the panthenol moisturizer can be selected from D-panthenol ([R]-2,4-dihydroxy-N-[3-hydroxypropyl)]- 3,3-dimethylbutamide), DL-panthenol, calcium pantothenate, royal jelly, panthetine, pantotheine, panthenyl ethyl ether, pangamic acid, pyridoxin, and pantoyl lactose.
  • compositions of the present invention additionally comprise a salt selected from alkali metal and alkaline earth metal salts, and mixtures thereof, preferably sodium, calcium and magnesium salts, and mixtures thereof. Especially preferred for use herein are calcium and magnesium salts.
  • the compositions herein preferably comprise from about 5ppm to about 500 ppm of the salt, based on the amount of metal ion.
  • the compositions herein may comprise additional enzymes selected from lipases, phospholipases, glycosidases, lactoperoxidases and cellulases, and mixtures thereof.
  • Neutralizing agents suitable for use in neutralizing acidic group containing hydrophilic gelling agents herein include sodium hydroxide, potassium hydroxide, ammonium hydroxide, monoethanolamine, diethanolamine, amino methyl propanol, tris-buffer and triethanolamine.
  • keratolytic agents include keratolytic agents; water-soluble or solubilizable preservatives preferably at a level of from about 0.1% to about 5%, such as Germall 115, methyl, ethyl, propyl and butyl esters of hydroxybenzoic acid, benzyl alcohol, DMDM hydantoin iodopropanyl butylcarbanate available under the trade name Glydant Plus from Lonza, EDTA, Euxyl (RTM) K400, Bromopol (2-bromo-2-nitropropane-l,3-diol) and phenoxypropanol; anti-bacterials such as Irgasan (RTM) and phenoxyethanol (preferably at levels of from 0.1% to about 5%); soluble or colloidally-soluble moisturising agents such as hylaronic acid and starch-grafted sodium polyacrylates such as Sanwet (RTM) J -1000, JVI-1500 and JJ
  • alpha hydroxy acids examples include glycolic acid, lactic acid, malic acid, citric acid, glycolic acid in conjunction with ammonium glycolate, alpha-hydroxy ethanoic acid, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, tri-alpOha hydroxy fruit acids, triple fruit acid, sugar cane extract, alpha hydroxy and botanical comprise, 1-alpha hydroxy acid and glycomer in crosslinked fatty acids alpha nutrium.
  • Preferred examples of alpha hydroxy acids are glycolic acid and lactic acid. It is preferred that alpha hydroxy acids are used in levels of upto 10%.
  • compositions of the present invention can additionally comprise from about 0.1 %> to about 5% by weight of aluminium starch octenylsuccinate.
  • Aluminium starch octenylsuccinate is the aluminium salt of the reaction product of octenylsuccinic anhydride with starch and is commercially available under the trade name from Dry Flo National Starch & Chemical Ltd. Dry Flo is useful herein from the viewpoint of skin feel and application characteristics.
  • a safe and effective amount of an anti-inflammatory agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 5%, more preferably from about 0.1 %> to about 2%, of the composition.
  • the anti-inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone or colour.
  • the exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti- inflammatory agent utilised since such agents vary widely in potency.
  • compositions of the subject invention can further include an anti-oxidant/radical scavenger.
  • the anti-oxidant/radical scavenger is especially useful for providing protection against UV radiation which can cause increased scaling or texture changes in the stratum corneum and against other environmental agents which can cause skin damage. Suitable amounts are from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition.
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts.
  • a chelating agent is especially useful for providing protection against UV radiation which can contribute to excessive scaling or skin texture changes and against other environmental agents which can cause skin damage.
  • a suitable amount is from about 0.01% to about 1%, more preferably from about 0.05% to about 0.5%>, of the composition.
  • Exemplary chelators that are useful herein are disclosed in U.S. Patent No. 5,487,884, incorporated herein by reference.
  • Preferred chelators useful in compositions of the subject invention are ethylenediamine tetraacetic acid (EDTA), furildioxime, and derivatives thereof.
  • the compositions of the present invention can also comprise a skin lightening agent.
  • compositions preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%, of a skin lightening agent.
  • Suitable skin lightening agents include those known in the art, including kojic acid, arbutin, ascorbic acid and derivatives thereof, e.g., magnesium ascorbyl phosphate.
  • Further skin lightening agents suitable for use herein also include those described in WO 95/34280 and WO 95/23780; each incorporated herein by reference.
  • water-soluble or solubilizable preservatives preferably at a level of from about 0.1% to about 5%, such as Germall 115, methyl, ethyl, propyl and butyl esters of hydroxybenzoic acid, benzyl alcohol, DMDM hydantoin iodopropanyl butylcarbanate available under the trade name Glydant Plus from Lonza, EDTA, Euxyl (RTM) K400, Bromopol (2-bromo-2-nitropropane- 1,3 -diol) and phenoxypropanol; anti- bacterials such as Irgasan (RTM) and phenoxyethanol (preferably at levels of from 0.1 %> to about 5%).
  • Antibacterial agents such as TCC/TCS, also known as triclosan and trichlorocarbon are also useful in compositions ofthe present invention.
  • compositions of the present invention comprise particulate materials having a refractive index of from about 1.3 to about 1.7, the particulate materials being dispersed in the composition and having a median particle size of from about 2 to about 30 ⁇ m.
  • the particulates useful herein have relatively narrow distributions, by which is meant that more than 50% of the particles fall within 3 ⁇ m either side of the respective median value.
  • Suitable particulate materials are organic or organosilicone and preferably organosilicone polymers.
  • Preferred particles are free-flowing, solid, materials.
  • solid is meant that the particles are not hollow. The void at the centre of hollow particles can have an adverse effect on refractive index and therefore the visual effects ofthe particles on either skin or the composition.
  • Suitable organic particulate materials include those made of polymethylsilsesquioxane, referenced above, polyamide, polythene, polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polystyrene, polytetrafluoroethylene (PTFE) and poly(vinylidene chloride). Copolymers derived from monomers of the aforementioned materials can also ' be used.
  • Inorganic materials include silica and boron nitride.
  • Tospearl® 145 which has a median particle size of about 4.5 ⁇ m and EA-209® from Kobo which is an ethylene / acrylic acid copolymer having a median particle size of about 10 ⁇ m, Nylon- 12 available under the trade name Orgasol 2002 from Elf Atochem, France, or mixtures thereof.
  • suitable pigments are titanium dioxide, predispersed titanium dioxide from Kobo e.g. Kobo GWL75CAP, iron oxides, acyglutamate iron oxides, ultramarine blue, D&C dyes, carmine, and mixtures thereof. Depending upon the type of composition, a mixture of pigments will normally be used.
  • the preferred pigments for use herein from the viewpoint of moisturisation, skin feel, skin appearance and emulsion compatibility are treated pigments.
  • the pigments can be treated with compounds such as amino acids, silicones, lecithin and ester oils.
  • the pH of the compositions herein is in the range from about 6.1 to about 10.0, preferably from about 7.0 to about 9.0, more preferably from about 8.0 to about 9.0 and even more preferably from about 8.0 to about 8.6. It is preferred that the pH of the final composition is adjusted by addition of acidic, basic or buffer salts as necessary.
  • the cosmetic compositions herein preferably have a water activity greater than 0.85, more preferably greater than 0.9, and most preferably greater than 0.95.
  • compositions of the invention are generally in emulsion form and are preferably formulated so as to have a product viscosity of at least about 4,000 mPa.s and preferably in the range from about 4,000 to about 1,000,000 mPa.s, more preferably from about 8,000 to about 350,000 mPa.s and especially from about 10,000 to about 250,000 mPa.s and even more especially from about 10,000 to about 150,000 mPa.s (25°C, neat, Brookfield RVT, T Spindle at 5 rpms and Heliopath Stand).
  • compositions of the present invention are stored in a pack comprising two or more chambers wherein the first chamber comprises a composition comprising: (a) from about from about 0.0001% to about 20%, preferably from about 0.01% to about 5%, more preferably from about 0.05% to about 2%, by weight, biologically active enzyme; (b) from about 20% to about 99%, preferably from about 50% to about 98%, more preferably from about 60 to about 95%, by weight, of a polyhydric alcohol; and (c) less than about 20% and preferably less than about 12%, by weight, of water; and wherein the second chamber comprises a placebo composition, preferably as an oil in water emulsion, and wherein the compositions from the two chambers are dispensed from the dispensing system simultaneously, preferably through a single nozzle.
  • the protease enzyme in highly stable conditions comprising high level of polyhydric alcohol whilst simultaneously dispensing a final composition in the form of an oil in water emulsion
  • the dispensing ratio ofthe pack By altering the dispensing ratio ofthe pack it is possible to control the level of enzyme that is dispensed with each dose. Furthermore when the compositions ofthe two chambers are dispensed they mix which results in a dilution ofthe enzyme storage composition and thus an increase in water activity which reactivates the enzyme. In addition, this dilution ofthe stored enzyme composition, means that the polyhydric alcohol levels ofthe final composition are low enough that the product has acceptable aesthetics.
  • the weight ratio ofthe composition dispensed from the first chamber ofthe multi chambered dispensing system and the second chamber ofthe multi chambered dispensing system is in the range from about 1 :1 to about 1:50, preferably from about 1 :5 to about 1 :30, more preferably from about 1 : 10 to about 1 :25 and most preferably from about 1: 15 to about 1:23.
  • compositions of the present invention are stored in such a multi chambered pack that the composition of the first chamber comprising the enzyme also comprises from about 50 to about 400ppm of a metal salt selected from the group consisting of alkali metal salts, alkaline earth metal salts and mixtures thereof. It is preferred that the metal salts are selected from salts of sodium, calcium, magnesium and mixtures thereof.
  • compositions of the present invention are useful for providing superior desquamation / skin exfoliation and thus improved skin softness benefits.
  • compositions of the present invention It is highly preferred a cosmetic method for treating the skin and / or hair which comprises administering a daily sequence of one or more unit doses of topical cosmetic composition over a repeating cycles is recommended for use of compositions of the present invention.
  • the preferred dosage sequence ofthe cycle comprises:
  • the cosmetic method of treatment is further characterised in that the dosage cycle is repeated for from about 1 to 1000 times, preferably from about 1 to 100 times, more preferably from about 1 to 12 times, even more preferably from about 1 to 6 times and most preferably from about 1 to 3 times in a single treatment period.
  • each daily dosage sequence of the regimen cycle can comprise one or more unit doses.
  • the cosmetic method within a given day, may comprise administering on one, or several occasions throughout the day, either the cosmetic composition comprising the biologically active compound or the placebo composition as appropriate depending upon the phase of the treatment cycle. Furthermore on each treatment occasion the user may be advised to administer one or more metered or unmetered doses ofthe appropriate composition.
  • a multi chambered pack is used such that throughout phase one ofthe treatment regimen the pack dispenses a mixture of a composition comprising a protease enzyme stabilised by high levels of polyhydric alcohol and a chassis oil in water emulsion comprising emollients and skin care active vitamin B 3 complex and that during phase two of the treatment regimen the pack dispenses the chassis oil in water emulsion alone.
  • compositions of the present invention are prepared by standard techniques well known to those skilled in the art. hi general the aqueous phase and/ or the oil phase would be prepared separately, with materials of similar phase partitioning being added in any order. If the final product is an emulsion, the two phases will then be combined with vigorous stirring. Any ingredients in the formulation with high volatility, or which are susceptible to hydrolysis at high temperatures, can be added with gentle stirring towards the end ofthe process, post emulsification if applicable.
  • Vitamin E Acetate Vitamin E Acetate
  • Isohexadecane Isohexadecane
  • Isopropyl Isostearate Cetyl Alcohol, Petrolatum, Ispropyl Palmitate, Behenyl Alcohol,
  • Cetearyl Glucoside/ Cetearyl Alcohol (if applicable) When the two mixtures are at 75-80C, add the mixtures together and mix at high shear to create an emulison.
  • compositions display excellent skin hydration, skin softness and skin smoothness benefits.

Abstract

L'invention concerne une composition cosmétique pour application topique à la peau ou aux cheveux, qui renferme: (a) entre environ 0,0001 % et environ 10 %, en poids, d'enzyme biologiquement active; (b) entre environ 0.1 % et environ 20 %, en poids, d'alcool polyhydrique; et (c) entre environ 0,1 % et environ 20 %, en poids, de principe actif pour les soins de la peau appartenant au groupe constitué de: composant à base de vitamine B3, panthénol, vitamine E, acétate de vitamine E, rétinol, propionate de rétinyle, palmitate de rétinyle, acide rétinoïque, vitamine C, théobromine, alpha-hydroxyacide, farnésol, phytantriol, acide salicylique, y compris des mélanges de ces substances. Les compositions considérées offrent une très bonne efficacité d'humidification, sans les niveaux élevés d'effet collant associé, ainsi que de bonnes propriétés rhéologiques et d'absorption, outre la sensation sur la peau, la douceur et le caractère lisse de la peau.
PCT/US2000/025085 2000-09-13 2000-09-13 Compositions cosmetiques WO2002022102A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA03002169A MXPA03002169A (es) 2000-09-13 2000-09-13 Composiciones cosmeticas.
CN00819889.6A CN1454080A (zh) 2000-09-13 2000-09-13 化妆品组合物
JP2002526354A JP2004508393A (ja) 2000-09-13 2000-09-13 化粧品組成物
AU2000274826A AU2000274826A1 (en) 2000-09-13 2000-09-13 Cosmetic compositions
PCT/US2000/025085 WO2002022102A1 (fr) 2000-09-13 2000-09-13 Compositions cosmetiques
EP00963410A EP1317249A1 (fr) 2000-09-13 2000-09-13 Compositions cosmetiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/025085 WO2002022102A1 (fr) 2000-09-13 2000-09-13 Compositions cosmetiques

Publications (1)

Publication Number Publication Date
WO2002022102A1 true WO2002022102A1 (fr) 2002-03-21

Family

ID=21741771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025085 WO2002022102A1 (fr) 2000-09-13 2000-09-13 Compositions cosmetiques

Country Status (6)

Country Link
EP (1) EP1317249A1 (fr)
JP (1) JP2004508393A (fr)
CN (1) CN1454080A (fr)
AU (1) AU2000274826A1 (fr)
MX (1) MXPA03002169A (fr)
WO (1) WO2002022102A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021350A1 (fr) * 2004-08-26 2006-03-02 Hans Schwarzkopf & Henkel Gmbh & Co. Kg Nouvel agent de traitement de fibres keratiniques
WO2017202586A1 (fr) 2016-05-26 2017-11-30 Unilever N.V. Compositions antimicrobiennes à usage topique
US20210032570A1 (en) * 2019-07-10 2021-02-04 Planet Lindsay, LLC Methods and compositions for reducing persistent odor in clothing and mitigating biofilms on various materials
US11357714B2 (en) 2020-07-21 2022-06-14 Chembeau LLC Diester cosmetic formulations and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220053609A (ko) * 2019-08-28 2022-04-29 다니스코 유에스 인크. 물 용매 결정화를 사용하여 수용액으로부터 메발론산 또는 이의 염 또는 락톤을 회수하는 방법 및 이의 조성물
CN113116750A (zh) * 2021-04-29 2021-07-16 广州睿森生物科技有限公司 一种多元醇组合物及其在化妆品中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508707A (en) * 1981-11-09 1985-04-02 Kakudai Shosan Kabushiki Kaisha Hair tonic composition
EP0755673A1 (fr) * 1995-07-25 1997-01-29 L'oreal Composition stable contenant un actif cosmétique et/ou dermatologique sensible à l'eau
WO1997027841A1 (fr) * 1996-01-31 1997-08-07 Gist-Brocades B.V. Utilisation de compositions comprenant des composes stabilises et efficaces sur le plan biologique
EP0839520A1 (fr) * 1996-11-04 1998-05-06 L'oreal Composition rinçable pour le soin de la peau
US5866158A (en) * 1992-08-03 1999-02-02 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
EP0968707A2 (fr) * 1998-07-03 2000-01-05 Beiersdorf Aktiengesellschaft Compositions contre l'acné et les comédons enflammés contenant des protéases de sérine et un ou plusieurs sels de calcium
FR2780645A1 (fr) * 1998-07-06 2000-01-07 Oreal Produit pour application topique contenant une lipase, un precurseur de vitamine et un alcool gras

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE990935A1 (en) * 1999-11-08 2002-04-03 Procter & Gamble Cosmetic Compositions
JP2001172155A (ja) * 1999-12-15 2001-06-26 Lion Corp 皮膚外用剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508707A (en) * 1981-11-09 1985-04-02 Kakudai Shosan Kabushiki Kaisha Hair tonic composition
US5866158A (en) * 1992-08-03 1999-02-02 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
EP0755673A1 (fr) * 1995-07-25 1997-01-29 L'oreal Composition stable contenant un actif cosmétique et/ou dermatologique sensible à l'eau
WO1997027841A1 (fr) * 1996-01-31 1997-08-07 Gist-Brocades B.V. Utilisation de compositions comprenant des composes stabilises et efficaces sur le plan biologique
US6117433A (en) * 1996-01-31 2000-09-12 Dsm N.V. Use of compositions comprising stabilized biologically effective compounds
EP0839520A1 (fr) * 1996-11-04 1998-05-06 L'oreal Composition rinçable pour le soin de la peau
US5932234A (en) * 1996-11-04 1999-08-03 L'oreal Rinsable skincare composition
EP0968707A2 (fr) * 1998-07-03 2000-01-05 Beiersdorf Aktiengesellschaft Compositions contre l'acné et les comédons enflammés contenant des protéases de sérine et un ou plusieurs sels de calcium
FR2780645A1 (fr) * 1998-07-06 2000-01-07 Oreal Produit pour application topique contenant une lipase, un precurseur de vitamine et un alcool gras

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021350A1 (fr) * 2004-08-26 2006-03-02 Hans Schwarzkopf & Henkel Gmbh & Co. Kg Nouvel agent de traitement de fibres keratiniques
WO2017202586A1 (fr) 2016-05-26 2017-11-30 Unilever N.V. Compositions antimicrobiennes à usage topique
US10869862B2 (en) 2016-05-26 2020-12-22 Conopco, Inc. Antimicrobial compositions for topical use
US20210032570A1 (en) * 2019-07-10 2021-02-04 Planet Lindsay, LLC Methods and compositions for reducing persistent odor in clothing and mitigating biofilms on various materials
US11357714B2 (en) 2020-07-21 2022-06-14 Chembeau LLC Diester cosmetic formulations and uses thereof
US11491092B2 (en) 2020-07-21 2022-11-08 Chembeau LLC Hair treatment formulations and uses thereof
US11801211B2 (en) 2020-07-21 2023-10-31 Chembeau LLC Hair treatment formulations and uses thereof

Also Published As

Publication number Publication date
AU2000274826A1 (en) 2002-03-26
MXPA03002169A (es) 2003-07-24
JP2004508393A (ja) 2004-03-18
EP1317249A1 (fr) 2003-06-11
CN1454080A (zh) 2003-11-05

Similar Documents

Publication Publication Date Title
US20030206897A1 (en) Cosmetic compositions
US20030157088A1 (en) Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care
US20030175232A1 (en) Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
EP1373296B1 (fr) Proteines provoquant une reaction immunogene modifiee, et methodes de production et d'utilisation desdites proteines
US8048859B2 (en) Use of repeat sequence protein polymers in personal care compositions
WO2001034111A1 (fr) Compositions cosmetiques
WO2002022099A1 (fr) Traitement cosmetique de la peau et/ou des cheveux
WO2002022102A1 (fr) Compositions cosmetiques
US20030211068A1 (en) Cosmetic method
EP1317248A1 (fr) Procede cosmetique
US20030206896A1 (en) Cosmetic method
WO2002022103A1 (fr) Compositions cosmetiques
IE990934A1 (en) Cosmetic Compositions
EP1317246A1 (fr) Traitement cosmetique
WO2004080426A2 (fr) Utilisation de polymeres de proteines a sequences recurrentes dans des compositions de soins personnels
JP2006525231A (ja) 皮膚用化粧品組成物
MXPA02004611A (es) Composiciones cosmeticas que se dejan en la piel que comrpenden en alcohol polihidrilico y un emulsificante que forma cristales liquidos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002526354

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002169

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008198896

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2000963410

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000963410

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000963410

Country of ref document: EP